CIC
DYN icon

Cornercap Investment Counsel’s Dyne Therapeutics DYN Stock Holding History

Cornercap Investment Counsel’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,938
Closed -$188K – 605
2023
Q3 		$188K Sell
20,938
-297
-1% -$3.2K 0.03% 497
2023
Q2 		$239K Buy
+21,235
New +$251K 0.04% 487
2022
Q4 		– Sell
-23,601
Closed -$300K – 585
2022
Q3 		$300K Sell
23,601
-4,050
-15% -$46.4K 0.06% 451
2022
Q2 		$190K Buy
+27,651
New +$190K 0.03% 491

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Cornercap Investment Counsel's DYN Position: Q4 2023 in Review

Cornercap Investment Counsel sold out of Dyne Therapeutics (DYN) in Q4 2023, closing a stake of 20,938 shares — an estimated $188K sold.

Cornercap Investment Counsel first reported a position in DYN in Q2 2022 and held it in 4 quarters. The position peaked at $300K in Q3 2022. 124 funds tracked by Wall St. Rank hold DYN as of Q4 2023.

  • Cornercap Investment Counsel reported no remaining Dyne Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cornercap Investment Counsel sold 20,938 Dyne Therapeutics shares in Q4 2023, an estimated $188K.
  • Cornercap Investment Counsel first reported a position in Dyne Therapeutics in Q2 2022 and held it in 4 quarters.
  • Cornercap Investment Counsel's Dyne Therapeutics position peaked at $300K in Q3 2022.
  • 124 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2023.

Based on Cornercap Investment Counsel's 13F filing for Q4 2023, filed 30 Jan 2024.